Form 4: James Healy of Sofinnova Investments Reports Common Stock Acquisitions in Rapport Therapeutics
SEC Form 4 Filing
James Healy, a director of Rapport Therapeutics, reports the acquisition of common stock through indirect holdings via several investment partnerships.
Summary
- On July 1, 2024, James Healy, a director of Rapport Therapeutics, reported the acquisition of common stock through various investment partnerships.
- The purchases were made indirectly through entities such as CRESTLINE SUMMIT PINNACLE MASTER, L.P., Crestline Summit Master, SPC CRESTLINE SUMMIT APEX SP, Crestline Summit Master, SPC PEAK SP, Sofinnova Venture Partners XI, L.P., and Sofinnova Synergy Master Fund LP.
- The transactions involved multiple purchases at weighted average prices ranging from $23.0755 to $26.0551 per share.
- The total number of shares acquired and the resulting beneficial ownership are detailed for each entity.
- Healy disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions, with neutral sentiment.
Industry Context
Form 4 filings are standard practice for insiders reporting transactions in their company's stock, providing transparency to the market.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of earliest transaction: Acquisition of common stock. |
| 07/03/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.